Summary

Clinical Trial Imaging Market Growth & Trends

The global clinical trial imaging market size is expected to reach USD 1.97 billion by 2030, registering a CAGR of 6.1% from 2024 to 2030, according to a new report by Grand View Research, Inc. Increasing research and development spending to discover new drugs and therapies to treat chronic diseases is propelling the industry growth. Images obtained from the internal examination of the body are used to determine drug activity. Clinical trial imaging provides rapid, detailed, and accurate screening. The need for clinical trial imaging is rapidly increasing in all phases of trials. Medical imaging in clinical trials is used as a primary, quantitative, and surrogate biomarker.

The clinical trial design includes selecting patient population, stratification based on biomarkers, different methods for allocation treatments, choosing efficient and reliable endpoints and validation of surrogate endpoints, calculating sample size, trial simulations, adaptive trial set-up, statistical and interim analysis, and assisting clients to deal with regulatory authorities such as EMA and FDA to discuss study design or defend study results.

Market players provide analytical testing services, pharmacokinetic, reading, and pharmacodynamics services for enhanced clinical development. IXICO offers advanced technologies for catalyzing clinical trials in neuroscience. Imaging biomarkers by the company help in measuring the safety and effectiveness of therapies used for neuro-imaging. Imaging biomarkers are effective in radiological reads. This provides the reading of MRI scans for central neuro to enhance the assessment of ongoing monitoring of drug safety and subject eligibility

Clinical Trial Imaging Market Report Highlights

• The project and data management services segment held the market with the largest revenue share of 28.73% in 2023 due to the growing requirement for data management and workflow for clinical trial imaging

• The operational imaging services segment also led the market with significant revenue share and are projected to grow the fastest CAGR of 7.32% from 2024 to 2030 and include imaging modalities such as MRI, CT scan, Ultrasound, Optical Coherence Tomography (OCT), X-rays, and others

• The oncology segment held the market with the largest revenue share of 28.98% in 2023. High prevalence of cancer cases and the constant need for new and innovative therapies to treat various types of cancer are expected to fuel the market growth.

• The contract research organizations (CROs) segment led the market with the largest revenue share of 45.95% in 2023 due to increasing investments in the field of research and development, snowballing outsourcing activities by the pharmaceutical and biotechnology companies to cut down the cost and time, and patent expiration

• North America dominated the market with a revenue share of 40.73% in 2023 due to the increasing geriatric population, along with chronic diseases and growing demand for treatment options.

ページTOPに戻る

Table of Contents

Table of Contents

Chapter 1. Clinical Trial Imaging Market: Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Service
1.1.2. Modality
1.1.3. Application
1.1.4. End Use
1.1.5. Regional scope
1.1.6. Estimates and forecast timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. GVR’s internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.3.5. Details of primary research
1.3.5.1. Data for primary interviews in North America
1.3.5.2. Data for primary interviews in Europe
1.3.5.3. Data for primary interviews in Asia Pacific
1.3.5.4. Data for primary interviews in Latin America
1.3.5.5. Data for Primary interviews in MEA
1.4. Information or Data Analysis
1.4.1. Data analysis models
1.5. Market Formulation & Validation
1.6. Model Details
1.6.1. Commodity flow analysis (Model 1)
1.6.1.1. Approach 1: Commodity flow approach
1.6.2. Volume price analysis (Model 2)
1.6.2.1. Approach 2: Volume price analysis
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
1.9.1. Objective 1
1.9.2. Objective 2
Chapter 2. Clinical Trial Imaging Market: Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Service outlook
2.2.2. Modality outlook
2.2.3. Application outlook
2.2.4. End use outlook
2.2.5. Regional outlook
2.3. Competitive Insights
Chapter 3. Clinical Trial Imaging Market: Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Industry Value Chain Analysis
3.3.1. Reimbursement framework
3.4. Market Dynamics
3.4.1. Market driver analysis
3.4.1.1. Growing number of pharmaceutical and biotechnological companies
3.4.1.2. Growing number of contract research organization (CRO)
3.4.1.3. Increasing research and development investments
3.4.2. Market restraint analysis
3.4.2.1. High cost of machineries and installations
3.5. X-ray Systems Market Analysis Tools
3.5.1. Industry Analysis - Porter’s
3.5.1.1. Supplier power
3.5.1.2. Buyer power
3.5.1.3. Substitution threat
3.5.1.4. Threat of new entrant
3.5.1.5. Competitive rivalry
3.5.2. PESTEL Analysis
3.5.2.1. Political landscape
3.5.2.2. Technological landscape
3.5.2.3. Economic landscape
3.5.3. Major Deals & Strategic Alliances Analysis
3.5.4. Market Entry Strategies
Chapter 4. Clinical Trial Imaging Market: Service Estimates & Trend Analysis
4.1. Definitions and Scope
4.1.1. Clinical Trial Design and Consultation Services
4.1.2. Reading and Analytical Services
4.1.3. Operational Imaging
4.1.3.1. Computed Tomography (CT) Scan
4.1.3.2. MRI (Magnetic Resonance Imaging)
4.1.3.3. X-ray
4.1.3.4. Ultrasound
4.1.3.5. Optical Coherence Tomography (OCT)
4.1.3.6. Others
4.1.4. System and Technology Support Services
4.1.5. Project and Data Management
4.2. Services Market Share, 2018 & 2030
4.3. Segment Dashboard
4.4. Global Clinical Trial Imaging Market by Product Outlook
4.5. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
4.5.1. Clinical Trial Design and Consultation Services
4.5.1.1. Clinical Trial Design and Consultation Services market estimates and forecast 2018 to 2030 (USD Million)
4.5.2. Reading and Analytical Services
4.5.2.1. Reading and Analytical Services market estimates and forecast 2018 to 2030 (USD Million)
4.5.3. Operational Imaging Services
4.5.3.1. Operational Imaging Services market estimates and forecast 2018 to 2030 (USD Million)
4.5.4. System and Technology Support Services
4.5.4.1. System and Technology Support Services market estimates and forecast 2018 to 2030 (USD Million)
4.5.5. Project and Data Management
4.5.5.1. Project and Data Management market estimates and forecast 2018 to 2030 (USD Million)
Chapter 5. Clinical Trial Imaging Market: Modality Estimates & Trend Analysis
5.1. Definitions and Scope
5.1.1. Computed Tomography
5.1.2. Magnetic Resonance Imaging
5.1.3. X-Ray
5.1.4. Ultrasound
5.1.5. Optical Coherence Tomography (OCT)
5.1.6. Others
5.2. Modality Market Share, 2018& 2030
5.3. Segment Dashboard
5.4. Clinical Trial Imaging Market by Modality Outlook
5.5. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
5.5.1. Computed Tomography
5.5.1.1. Computed tomography estimates and forecast 2018 to 2030 (USD Million)
5.5.2. Magnetic Resonance Imaging
5.5.2.1. Magnetic resonance imaging estimates and forecast 2018 to 2030 (USD Million)
5.5.3. X-Ray
5.5.3.1. X-Ray market estimates and forecast 2018 to 2030 (USD Million)
5.5.4. Ultrasound
5.5.4.1. Ultrasound market estimates and forecast 2018 to 2030 (USD Million)
5.5.5. Optical Coherence Tomography (OCT)
5.5.5.1. Optical coherence tomography (OCT) market estimates and forecast 2018 to 2030 (USD Million)
5.5.6. Others
5.5.6.1. Others market estimates and forecast 2018 to 2030 (USD Million)
Chapter 6. Clinical Trial Imaging Market: Application Estimates & Trend Analysis
6.1. Definitions and Scope
6.1.1. Nonalcoholic Steatohepatitis (NASH)
6.1.2. Chronic Kidney Disease (CKD)
6.1.3. Diabetes
6.1.4. Cardiovascular Diseases
6.1.5. Ophthalmology
6.1.6. Musculoskeletal
6.1.7. Oncology
6.1.8. Gastroenterology
6.1.9. Pediatrics
6.1.10. Others
6.2. Application Market Share, 2018& 2030
6.3. Segment Dashboard
6.4. Clinical Trial Imaging Market by Application Outlook
6.5. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
6.5.1. Nonalcoholic Steatohepatitis (NASH)
6.5.1.1. Nonalcoholic steatohepatitis estimates and forecast 2018 to 2030 (USD Million)
6.5.2. Chronic Kidney Disease
6.5.2.1. Chronic kidney disease estimates and forecast 2018 to 2030 (USD Million)
6.5.3. Diabetes
6.5.3.1. Diabetes market estimates and forecast 2018 to 2030 (USD Million)
6.5.4. Cardiovascular Diseases
6.5.4.1. Cardiovascular diseases market estimates and forecast 2018 to 2030 (USD Million)
6.5.5. Ophthalmology
6.5.5.1. Ophthalmology market estimates and forecast 2018 to 2030 (USD Million)
6.5.6. Oncology
6.5.6.1. Oncology market estimates and forecast 2018 to 2030 (USD Million)
6.5.7. Musculoskeletal
6.5.7.1. Musculoskeletal market estimates and forecast 2018 to 2030 (USD Million)
6.5.8. Gastroenterology
6.5.8.1. Gastroenterology market estimates and forecast 2018 to 2030 (USD Million)
6.5.9. Pediatrics
6.5.9.1. Pediatrics market estimates and forecast 2018 to 2030 (USD Million)
6.5.10. Others
6.5.10.1. Others market estimates and forecast 2018 to 2030 (USD Million)
Chapter 7. Clinical Trial Imaging Market: End Use Estimates & Trend Analysis
7.1. Definitions and Scope
7.1.1. Biotechnology and Pharmaceutical Companies
7.1.2. Medical Devices Manufacturers
7.1.3. Academic and Government Research Institutes
7.1.4. Contract Research Organization (CRO)
7.1.5. Others
7.2. End Use Market Share, 2018 & 2030
7.3. Segment Dashboard
7.4. Clinical Trial Imaging Market by End Use Outlook
7.5. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
7.5.1. Biotechnology and Pharmaceutical Companies
7.5.1.1. Biotechnology and pharmaceutical companies estimates and forecast 2018 to 2030 (USD Million)
7.5.2. Medical Devices Manufacturers
7.5.2.1. Medical devices manufacturers estimates and forecast 2018 to 2030 (USD Million)
7.5.3. Academic and Government Research Institutes
7.5.3.1. Academic and government research institutes market estimates and forecast 2018 to 2030 (USD Million)
7.5.4. Contract Research Organization (CRO)
7.5.4.1. Contract research organization (CRO) market estimates and forecast 2018 to 2030 (USD Million)
7.5.5. Others
7.5.5.1. Others market estimates and forecast 2018 to 2030 (USD Million)
Chapter 8. Clinical Trial Imaging Market: Regional Estimates & Trend Analysis
8.1. Regional Market Share Analysis, 2023 & 2030
8.2. Regional Market Dashboard
8.3. Global Regional Market Snapshot
8.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
8.5. North America
8.5.1. U.S.
8.5.1.1. Key country dynamics
8.5.1.2. Regulatory framework/ reimbursement structure
8.5.1.3. Competitive scenario
8.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
8.5.2. Canada
8.5.2.1. Key country dynamics
8.5.2.2. Regulatory framework/ reimbursement structure
8.5.2.3. Competitive scenario
8.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
8.6. Europe
8.6.1. UK
8.6.1.1. Key country dynamics
8.6.1.2. Regulatory framework/ reimbursement structure
8.6.1.3. Competitive scenario
8.6.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
8.6.2. Germany
8.6.2.1. Key country dynamics
8.6.2.2. Regulatory framework/ reimbursement structure
8.6.2.3. Competitive scenario
8.6.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
8.6.3. France
8.6.3.1. Key country dynamics
8.6.3.2. Regulatory framework/ reimbursement structure
8.6.3.3. Competitive scenario
8.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
8.6.4. Italy
8.6.4.1. Key country dynamics
8.6.4.2. Regulatory framework/ reimbursement structure
8.6.4.3. Competitive scenario
8.6.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
8.6.5. Spain
8.6.5.1. Key country dynamics
8.6.5.2. Regulatory framework/ reimbursement structure
8.6.5.3. Competitive scenario
8.6.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
8.6.6. Norway
8.6.6.1. Key country dynamics
8.6.6.2. Regulatory framework/ reimbursement structure
8.6.6.3. Competitive scenario
8.6.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
8.6.7. Sweden
8.6.7.1. Key country dynamics
8.6.7.2. Regulatory framework/ reimbursement structure
8.6.7.3. Competitive scenario
8.6.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
8.6.8. Denmark
8.6.8.1. Key country dynamics
8.6.8.2. Regulatory framework/ reimbursement structure
8.6.8.3. Competitive scenario
8.6.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
8.7. Asia Pacific
8.7.1. Japan
8.7.1.1. Key country dynamics
8.7.1.2. Regulatory framework/ reimbursement structure
8.7.1.3. Competitive scenario
8.7.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
8.7.2. China
8.7.2.1. Key country dynamics
8.7.2.2. Regulatory framework/ reimbursement structure
8.7.2.3. Competitive scenario
8.7.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
8.7.3. India
8.7.3.1. Key country dynamics
8.7.3.2. Regulatory framework/ reimbursement structure
8.7.3.3. Competitive scenario
8.7.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
8.7.4. Australia
8.7.4.1. Key country dynamics
8.7.4.2. Regulatory framework/ reimbursement structure
8.7.4.3. Competitive scenario
8.7.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
8.7.5. South Korea
8.7.5.1. Key country dynamics
8.7.5.2. Regulatory framework/ reimbursement structure
8.7.5.3. Competitive scenario
8.7.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
8.7.6. Thailand
8.7.6.1. Key country dynamics
8.7.6.2. Regulatory framework/ reimbursement structure
8.7.6.3. Competitive scenario
8.7.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
8.8. Latin America
8.8.1. Brazil
8.8.1.1. Key country dynamics
8.8.1.2. Regulatory framework/ reimbursement structure
8.8.1.3. Competitive scenario
8.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
8.8.2. Mexico
8.8.2.1. Key country dynamics
8.8.2.2. Regulatory framework/ reimbursement structure
8.8.2.3. Competitive scenario
8.8.2.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
8.8.3. Argentina
8.8.3.1. Key country dynamics
8.8.3.2. Regulatory framework/ reimbursement structure
8.8.3.3. Competitive scenario
8.8.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
8.9. MEA
8.9.1. South Africa
8.9.1.1. Key country dynamics
8.9.1.2. Regulatory framework/ reimbursement structure
8.9.1.3. Competitive scenario
8.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
8.9.2. Saudi Arabia
8.9.2.1. Key country dynamics
8.9.2.2. Regulatory framework/ reimbursement structure
8.9.2.3. Competitive scenario
8.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
8.9.3. UAE
8.9.3.1. Key country dynamics
8.9.3.2. Regulatory framework/ reimbursement structure
8.9.3.3. Competitive scenario
8.9.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
8.9.4. Kuwait
8.9.4.1. Key country dynamics
8.9.4.2. Regulatory framework/ reimbursement structure
8.9.4.3. Competitive scenario
8.9.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 9. Competitive Landscape
9.1. Recent Developments & Impact Analysis, By Key Market Participants
9.2. Company/Competition Categorization
9.2.1. Innovators
9.3. Vendor Landscape
9.3.1. List of key distributors and channel partners
9.3.2. Key customers
9.3.3. Key company market share analysis, 2023
9.3.4. IXICO plc
9.3.4.1. Company overview
9.3.4.2. Financial performance
9.3.4.3. Product benchmarking
9.3.4.4. Strategic initiatives
9.3.5. Navitas Life Sciences
9.3.5.1. Company overview
9.3.5.2. Financial performance
9.3.5.3. Product benchmarking
9.3.5.4. Strategic initiatives
9.3.6. Resonance Health
9.3.6.1. Company overview
9.3.6.2. Financial performance
9.3.6.3. Product benchmarking
9.3.6.4. Strategic initiatives
9.3.7. ProScan Imaging
9.3.7.1. Company overview
9.3.7.2. Financial performance
9.3.7.3. Product benchmarking
9.3.7.4. Strategic initiatives
9.3.8. Radiant Sage LLC
9.3.8.1. Company overview
9.3.8.2. Financial performance
9.3.8.3. Product benchmarking
9.3.8.4. Strategic initiatives
9.3.9. Medpace
9.3.9.1. Company overview
9.3.9.2. Financial performance
9.3.9.3. Product benchmarking
9.3.9.4. Strategic initiatives
9.3.10. Biomedical Systems Corp.
9.3.10.1. Company overview
9.3.10.2. Financial performance
9.3.10.3. Product benchmarking
9.3.10.4. Strategic initiatives
9.3.11. Cardiovascular Imaging Technologies
9.3.11.1. Company overview
9.3.11.2. Financial performance
9.3.11.3. Product benchmarking
9.3.11.4. Strategic initiatives
9.3.12. Intrinsic Imaging
9.3.12.1. Company overview
9.3.12.2. Financial performance
9.3.12.3. Product benchmarking
9.3.12.4. Strategic initiatives
9.3.13. BioTelemetry
9.3.13.1. Company overview
9.3.13.2. Financial performance
9.3.13.3. Product benchmarking
9.3.13.4. Strategic initiatives